RAD1 and neoplasm: Currently, a few diagnostics markers are available, namely circulating cancer cells in the blood CTCs (circulating tumor cells), epigenetic markers such as ADAMTS1 (disintegrin A and metalloproteinases with thrombospondin motifs), tumor markers such as CA19-9 (cancer antigen 19-9), autoantibodies such as anti-MUC1 (mucin 1), ENOA1/2 (alfa-enolase), or against RAD1 (RAD1 checkpoint DNA exonuclease) for the early diagnosis of the disease and assessment of prognosis, and microRNAs such as miR-196a, miR-221, and miR-155 [39,41].